About Us

We are Vivodyne.

Vivodyne is a biotechnology company that's changing how scientists study human biology and develop therapeutics.

our VISION

Inventing the
future of medicine

The next frontier of therapeutics development hinges on achieving greater preclinical certainty before drugs enter clinical trials — especially as these drugs become more precise and human-specific. This is biotech’s biggest challenge and our company's critical focus.

Solving this requires not only one breakthrough, but a combination of three: complex human tissue engineering, highly scalable robotics, and cutting-edge AI models. These serve as the core pillars that allow us to generate predictive human data before clinical trials.

By leveraging our platform, we bring safer and more effective treatments to patients in need. At Vivodyne, we are proud to be at the forefront of developing life-saving therapies against human diseases.

Technician prepares for a single cell sequencing analysis using samples from organs on chips Close up of blinking eye organ on chip model with functional eyelidOrgan on chip model under confocal microscope
Bone marrow organ on a chip model under confocal microscopeKuka’s robotic arm moving biological samplesBone marrow organ on a chip model mobilizing neutrophils under confocal microscope
Technician prepares for a single cell sequencing analysis using samples from organs on chips
 Close up of blinking eye organ on chip model with functional eyelid
Organ on chip model under confocal microscope
Bone marrow organ on a chip model under confocal microscope
Kuka’s robotic arm moving biological samples
Bone marrow organ on a chip model mobilizing neutrophils under confocal microscope

Meet our leadership team.

Andrei Georgescu, Ph.D.
CEO / Co-Founder

Dr. Georgescu spearheads Vivodyne’s vision of reshaping therapeutics development. The loss of translation between animal studies and human trials compelled him to co-found Vivodyne in 2020 and create an entirely new platform from the ground up. With a Ph.D. from Dr. Huh’s esteemed organ-chip research group at the University of Pennsylvania, his expertise lies in human-tissue engineering, robotics, and machine learning. His prior achievements include sending lab-grown tissues with NASA to space and developing DNA synthesis chips that remain industry staples to this day.

Dan Huh, Ph.D.
CSO / Co-Founder

Dr. Dan Huh is an internationally acclaimed bioengineer and designer widely known as a pioneer of organ-on-a-chip technology. While at Harvard he published a paper in Science presenting the first “lung-on-a-chip” model as a proof of concept that ultimately kickstarted the whole field of organs-on-chips. He is a renowned Professor in the Department of Bioengineering at the University of Pennsylvania. At Vivodyne, his research group focuses on developing new and innovative microengineered models of human physiological systems. His work has been recognized by many awards, including the Bernard Langer Distinguished Lectureship, Lush Prize, and the McPherson Distinguished Lectureship, just to name a few.

Elliot Menschik, M.D., Ph.D.
Chief Technology Officer

Elliot is a physician, scientist, engineer, repeat founder/executive, and startup investor. At Vivodyne, he's responsible for technology development and operations that unify software, hardware, data, AI, and infrastructure to form the company's platform. Previously, he was the founding Chief Digital Officer at Resilience, where he scaled the biomanufacturing startup from inception to 3,000+ workers in 3 years, and was responsible for all things #techbio across enterprise, lab, and cGMP manufacturing domains. Earlier, he was at Amazon Web Services where he founded and led their specialization initiative for the worldwide biotech ecosystem, working with startups across cloud, automation, HPC, AI, biology, and chemistry.

Susan Billings, Ph.D.
Chief Commercial Officer

Dr. Susan Billings is an accomplished commercial leader and stands at the forefront of the global life science sector, steering Vivodyne through the complex landscape of client relationships, technology innovation, and commercial strategy. Her extensive professional background includes a notable 11-year tenure at Curia, where she served as Vice President & Global Head of Business Development and led global business development teams to drive rapid growth with partnerships across the company’s diverse services. She earned her doctorate from UC Irvine in organic chemistry, and has prior experiences advancing through technical and operational roles at an oncology start-up and Merck.

Anthony Bahinksi, Ph.D.
Chief Biotechnology Officer

Dr. Bahinski’s career spans academic research and large pharma, with more than 25 years of experience in the pharmaceutical industry. He served on the Advanced Technology Team at Harvard’s Wyss Institute, leading DARPA, and FDA collaborative efforts in development of organ chip systems. He has also served on several advisory boards and is currently member of the Science Board of the US FDA and formerly of the US EPA Board of Scientific Counselors. He is a member of the Editorial Board of the journal Applied In Vitro Toxicology. Dr. Bahinski is author/co-author of over 45 publications including peer-reviewed articles and book chapters.

Ivana Mikic, Ph.D.
VP of Artificial Intelligence

Dr. Ivana Mikic leads the team behind Viovodyne’s AI platform with a focus on developing machine learning tools and cloud-based infrastructure to solve big data problems in drug discovery. Previously, Dr Mikić has led AI and software teams that developed highly successful solutions for digital pathology, high-content screening and computer vision tools for biomedical applications, resulting in two successful acquisitions. Former Ramón y Cajal Professor of computer vision at Universidad Autónoma de Madrid, Dr Mikić holds a PhD in Electrical and Computer Engineering from UC San Diego.

Julie O’Shaughnessy
VP of Operations

Julie is a leader known for building robust operational frameworks, fostering healthy organizational cultures, and cultivating high-performing teams. At Vivodyne, she leads Business Operations, Strategic Planning, Finance, and People. Most recently at Resilience, she architected and led the Operations functions that enabled the digital scale up across multiple sites and 3,000+ workers. Previously at AWS, she founded the Global Operations team to support enterprise customers, and then went on to lead Global Strategy and Operations for the Startup & VC arm of the business. Julie is Vice Chair of the Board at the Ali Forney Center and an Executive Committee member for the University of New Hampshire Athletics Board.

Andrei Georgescu, Ph.D.
CEO / Co-Founder

Dr. Georgescu spearheads Vivodyne’s vision of reshaping therapeutics development. The loss of translation between animal studies and human trials compelled him to co-found Vivodyne in 2020 and create an entirely new platform from the ground up. With a Ph.D. from Dr. Huh’s esteemed organ-chip research group at the University of Pennsylvania, his expertise lies in human-tissue engineering, robotics, and machine learning. His prior achievements include sending lab-grown tissues with NASA to space and developing DNA synthesis chips that remain industry staples to this day.

Dan Huh, Ph.D.
CSO / Co-Founder

Dr. Dan Huh is an internationally acclaimed bioengineer and designer widely known as a pioneer of organ-on-a-chip technology. While at Harvard he published a paper in Science presenting the first “lung-on-a-chip” model as a proof of concept that ultimately kickstarted the whole field of organs-on-chips. He is a renowned Professor in the Department of Bioengineering at the University of Pennsylvania. At Vivodyne, his research group focuses on developing new and innovative microengineered models of human physiological systems. His work has been recognized by many awards, including the Bernard Langer Distinguished Lectureship, Lush Prize, and the McPherson Distinguished Lectureship, just to name a few.

Elliot Menschik, M.D., Ph.D.
Chief Technology Officer

Elliot is a physician, scientist, engineer, repeat founder/executive, and startup investor. At Vivodyne, he's responsible for technology development and operations that unify software, hardware, data, AI, and infrastructure to form the company's platform. Previously, he was the founding Chief Digital Officer at Resilience, where he scaled the biomanufacturing startup from inception to 3,000+ workers in 3 years, and was responsible for all things #techbio across enterprise, lab, and cGMP manufacturing domains. Earlier, he was at Amazon Web Services where he founded and led their specialization initiative for the worldwide biotech ecosystem, working with startups across cloud, automation, HPC, AI, biology, and chemistry.

Susan Billings, Ph.D.
Chief Commercial Officer

Dr. Susan Billings is an accomplished commercial leader and stands at the forefront of the global life science sector, steering Vivodyne through the complex landscape of client relationships, technology innovation, and commercial strategy. Her extensive professional background includes a notable 11-year tenure at Curia, where she served as Vice President & Global Head of Business Development and led global business development teams to drive rapid growth with partnerships across the company’s diverse services. She earned her doctorate from UC Irvine in organic chemistry, and has prior experiences advancing through technical and operational roles at an oncology start-up and Merck.

Anthony Bahinksi, Ph.D.
Chief Biotechnology Officer

Dr. Bahinski’s career spans academic research and large pharma, with more than 25 years of experience in the pharmaceutical industry. He served on the Advanced Technology Team at Harvard’s Wyss Institute, leading DARPA, and FDA collaborative efforts in development of organ chip systems. He has also served on several advisory boards and is currently member of the Science Board of the US FDA and formerly of the US EPA Board of Scientific Counselors. He is a member of the Editorial Board of the journal Applied In Vitro Toxicology. Dr. Bahinski is author/co-author of over 45 publications including peer-reviewed articles and book chapters.

Ivana Mikic, Ph.D.
VP of Artificial Intelligence

Dr. Ivana Mikic leads the team behind Viovodyne’s AI platform with a focus on developing machine learning tools and cloud-based infrastructure to solve big data problems in drug discovery. Previously, Dr Mikić has led AI and software teams that developed highly successful solutions for digital pathology, high-content screening and computer vision tools for biomedical applications, resulting in two successful acquisitions. Former Ramón y Cajal Professor of computer vision at Universidad Autónoma de Madrid, Dr Mikić holds a PhD in Electrical and Computer Engineering from UC San Diego.

Julie O’Shaughnessy
VP of Operations

Julie is a leader known for building robust operational frameworks, fostering healthy organizational cultures, and cultivating high-performing teams. At Vivodyne, she leads Business Operations, Strategic Planning, Finance, and People. Most recently at Resilience, she architected and led the Operations functions that enabled the digital scale up across multiple sites and 3,000+ workers. Previously at AWS, she founded the Global Operations team to support enterprise customers, and then went on to lead Global Strategy and Operations for the Startup & VC arm of the business. Julie is Vice Chair of the Board at the Ali Forney Center and an Executive Committee member for the University of New Hampshire Athletics Board.

Your most innovative work starts here.

We're building a culture at Vivodyne where ambitious people can do their best work. Check out our exciting job openings, and see what it's like to work with us.

Join our team